Both β-catenin and Ras were reduced by KY1022 treatment in various CRC cell lines (WiDR, DLD-1, HCT15, SW480, and LoVo) expressing either wild-type or mutant K-Ras (Figure 2F). This evidence concerns the gene KRAS and colorectal carcinoma.